Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though ...

Analysts have previously suggested that Lumakras could become a $1 billion-plus product if Amgen can extend the label for the drug into the first-line NSCLC setting and also get approval for the ...

While the wording on the label is almost the same, Mirati reckons its drug has an efficacy and pharmacodynamic profile that will help it catch up with Lumakras, which brought in $210 million in ...

HAIKOU, August 24. /TASS/. An innovative American drug Lumakras (also known as Sotorasib) for lung cancer and other types of cancer may soon become available at Hainan Lecheng Medical Cluster ...